Clinical Trial Update: A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of mirikizumab in active Crohn's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-02-28